Ryvu Therapeutics SA (RVU)

Currency in PLN
18.20
-0.30(-1.62%)
Delayed Data·
Earnings results expected in 14 days
RVU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
18.0618.46
52 wk Range
13.6431.90
Key Statistics
Bid/Ask
18.06 / 18.20
Prev. Close
18.5
Open
18.26
Day's Range
18.06-18.46
52 wk Range
13.64-31.9
Volume
7.89K
Average Volume (3m)
50.8K
1-Year Change
-36.8056%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RVU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.62
Upside
+84.73%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Ryvu Therapeutics SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

1 Buy
3 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 33.62
(+84.73% Upside)

Earnings

Latest Release
20-05-2026
EPS / Forecast
-0.55 / --
Revenue / Forecast
21.7M / --
EPS Revisions
Last 90 days

RVU Income Statement

Compare RVU to Peers and Sector

Metrics to compare
RVU
Peers
Sector
Relationship
P/E Ratio
−4.8x−3.2x−0.4x
PEG Ratio
−0.160.020.00
Price/Book
10.3x3.2x2.6x
Price / LTM Sales
4.8x2.2x3.1x
Upside (Analyst Target)
58.6%24.6%46.0%
Fair Value Upside
Unlock18.8%5.3%Unlock

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company’s early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu’s STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Employees
228
Market
Poland

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.38M27.60%119.95M
Other Institutional Investors
5.34M23.12%100.47M
Public Companies & Retail Investors
11.40M49.29%214.24M
Total
23.12M100.00%434.66M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
PTE Allianz Polska SA9.22%21,32,54040,092
Allianz Polska OFE9.22%21,32,54040,092

FAQ

What Is the Ryvu (RVU) Share Price Today?

The Ryvu share price today is 18.20.

What is the current Ryvu (RVU) share price and day range?

As of 27-08-2026, the Ryvu share price is 18.20, with a previous close of 18.50. The share price has ranged from 18.06 to 18.46 today, while the 52-week range spans from 13.64 to 31.90.

What Is the Ryvu Market Cap?

As of today, Ryvu market cap is 421.25M.

What Is the Ryvu (RVU) Share Price Target?

The average 12-month share price target for Ryvu is 33.62, with a high estimate of 49.1 and a low estimate of 17. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +84.73% Upside potential.

What Is Ryvu's Earnings Per Share (TTM)?

The Ryvu EPS (TTM) is -3.84.

When Is the Next Ryvu Earnings Date?

Ryvu will release its next earnings report on 10-09-2026.

From a Technical Analysis Perspective, Is RVU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Ryvu Trade On?

Ryvu is listed and trades on the Warsaw Stock Exchange.

What Is the Stock Symbol for Ryvu?

The stock symbol for Ryvu is "RVU."

How Many Times Has Ryvu Stock Split?

Ryvu has split 0 times.

How Many Employees Does Ryvu Have?

Ryvu has 228 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.